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Abstract: TGFβ (transforming growth factor-beta) is a pleotropic cytokine with contrasting effects in
cancer. In normal tissue and early tumours, TGFβ acts as a tumour suppressor, limiting proliferation
and inducing apoptosis. However, these effects are eventually abrogated by the loss or inactivation of
downstream signalling within the TGFβ pathway, and in established tumours, TGFβ then acts as
a tumour promotor through multiple mechanisms including inducing epithelial-to-mesenchymal
transition (EMT), promoting formation of cancer-associated fibroblasts (CAFs) and increasing
angiogenesis. TGFβ is secrereted as a large latent complex and is embedded in the extracellular
matrix or held on the surface of cells and must be activated before mediating its multiple functions.
Thus, whilst TGFβ is abundant in the tumour microenvironment (TME), its functionality is regulated
by local activation. The αv-integrins are major activators of latent-TGFβ. The potential benefits of
manipulating the immune TME have been highlighted by the clinical success of immune-checkpoint
inhibitors in a number of solid tumour types. TGFβ is a potent suppressor of T-cell-mediated immune
surveillance and a key cause of resistance to checkpoint inhibitors. Therefore, as certain integrins
locally activate TGFβ, they are likely to have a role in the immunosuppressive TME, although
this remains to be confirmed. In this review, we discussed the role of TGFβ in cancer, the role
of integrins in activating TGFβ in the TME, and the potential benefits of targeting integrins to
augment immunotherapies.
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1. Introduction
The extracellular matrix (ECM) serves both as a scaffold for cells and as an information-rich
system that cells decipher through interacting sensory inputs in which integrins and transforming
growth factor-beta (TGFβ) are highly influential [1]. Homeostasis regulates the balance of cytokines
and cell surface receptors to mediate intricate interactions between cells and the ECM. TGFβ is the
most pleiotropic known cytokine and almost every cell produces TGFβ and has receptors for it [2,3].
It is an effective growth inhibitor of epithelial, haematopoietic and immune cells and is locally activated
during tissue remodelling to regulate growth and repair. Dysregulation of TGFβ is implicated in
a number of pathologies, most notably cancer and tissue fibrosis [3,4]. Whilst almost ubiquitously
secreted, TGFβ is held within the ECM in an inactive state, requiring activation to mediate its effects.
As discussed below, the αvβ integrins are major activators of TGFβ in both normal tissue and cancer.
Integrins are heterodimers that mediate bidirectional signalling across cell membranes, coupling
diverse extracellular ligands to the cytoskeleton [1,5,6]. Integrin ectodomains comprise an α- and
β-subunit non-covalently joined at the head, each connected to a flexible leg which traverses the cell
membrane to a short cytoplasmic domain (Figure 1) [7]. The endodomains link with cytoskeletal
components and thus allow integrins to act as mechanotransducers between the cell and ECM [8–10].
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Regulation of ligand affinity and signalling is mediated by a series of coupled motions of the headpiece
with leg domains that change the overall shape from bent to extended [11]. Integrin structure is
described in three main conformations—bent-closed, extended-closed, or extended-open, with low
ligand affinity when in the bent state [10,12]. A total of 24 different αβ heterodimers exist, composed
of 18 α- and 8 β-subunits, each with different functional and tissue specificity. The primary binding
site of integrins to their target ligands is via recognition of short peptide motifs, the most common of
which is arginine-glycine-aspartic acid (RGD) motif; eight integrins (αIIβ3, α5β1, α8β1, αvβ1, αvβ3,
αvβ5, αvβ6, αvβ8) recognize the RGD motif [13].
Figure 1. Integrin αvβ6 conformation states. Integrins comprise an α- and β-subunit associated
non-covalently at the head, each connected to a flexible leg that traverses the cell membrane to a short
cytoplasmic domain. Ligand affinity is mediated by changes in conformation, with affinity highest in
the extended-open state and lowest in the bent-closed state. The black arrows indicate the direction of
force that integrins mediate between the extracellular matrix and actin cytoskeleton adapted from [9].
Integrin functions are myriad and include cell adhesion, migration, proliferation, differentiation,
survival and invasion but the αv-integrins, particularly αvβ6 and αvβ8, are specialised to activate
TGFβ [14]. Since integrins and their ligands are amongst the plethora of TGFβ-regulated transcriptional
targets, TGFβ-integrin interactions are bilateral.
In this review, we discussed TGFβ activation by integrins and its consequences by promoting
cancer through regulating the the immune and non-immune tumour microenvironment (TME).
2. TGFβ Structure and Secretion
The transforming growth factor β (TGFβ) family is encoded by 33 genes and includes the three
TGFβ isoforms (TGFβ1, TGFβ2, TGFβ3) relevant to this review [15–17]. The three isoforms are 75%
homologous with similar signalling activities but have variable expression in different cells and tissues,
and distinct phenotypes are observed in vivo in knockout models [18]. TGFβ1 is predominantly
expressed in endothelial, hematopoietic, and connective-tissue cells, TGFβ2 in epithelial and neuronal
cells, and TGFβ3 in mesenchymal cells [19]. TGFβ1 is the most abundant, most widely studied,
and most commonly dysregulated isoform in cancer [20,21], and thus, will be the focus of this review.
TGFβ is initially translated as a propeptide comprising the growth factor and latency-associated
peptide (LAP). A disulphide-linked dimer of the propeptide is formed, which is cleaved by furin to
release the mature TGFβ from LAP. However, the affinity of the propeptide LAP for TGFβ is such
that it assembles into a non-covalent complex, termed the small latent complex (SLC) that comprises
TGF-β and homodimers of LAP (Figure 2) [2,16,22]. The SLC is then further processed before it exits
the cell. In non-leukocyte cells, a pair of disulphide bonds link LAP to a latent-TGFβ binding protein
(LTBP) [22]. LTBPs are large glycoproteins that serve as chaperones for pro-TGFβ by enhancing folding
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and secretion [22]. In leukocytes, the glycoprotein-A repetitions predominant protein (GARP) bind
to LAP, again via two disulphide linkages and again serving as chaperone for correct presentation
of the complex [23–25]. As GARP is a transmembrane molecule, it holds the SLC at the membrane
(discussed in [25]). Thus, TGF-β is secreted as a tripartite complex of TGF-β, LAP and either LTBP or
GARP, termed the large latent complex (LLC) [9,22,26]. Once secreted, LTBPs localise latent-TGFβ
to the ECM by interactions with fibronectin and fibrillin [22,27], the four LTBPs being expressed in
a tissue specific fashion [2]. The majority of latent-TGFβ is sequestered within the ECM, with the
remaining latent-TGFβ anchored to immune cell surfaces or stored in α-granules within platelets and
mast cells [28].
Figure 2. TGFβ (transforming growth factor-beta) structure and secretion. Dimers of TGFβ and
latency-associated peptide (LAP) linked by non-covalent bonds form the small latent complex (SLC).
Left: Covalent bonds link the small latent complex to latent TGFβ binding protein (LTBP) which
together form the large latent complex (LLC). Once secreted, TGFβ is held in an inactive state, anchored
by LTBP to fibronectin and fibrillin in the extracellular matrix. Right: In some cells, notably regulatory
T-cells, the SLC binds covalently to glycoprotein-A repititions predominant (GARP), and following
secretion is bound to the cell membrane. Adapted from [15,16,29]. SS, disulphide bonds.
3. TGFβ Activation
TGFβ is stored within the ECM at concentrations that are several orders of magnitude higher
than required to produce potent biological effects [30]. Thus, most TGFβ regulation occurs at the
level of activation of latent-TGFβ sequestered within the ECM by LTBP or on cell-surface scaffold
proteins by GARP [9,22,26,30]. Active TGFβ has a considerably shorter half-life than latent TGFβ
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and is rapidly cleared from the extracellular space if not associated with its receptor [31]. Thus,
the activation of latent-TGFβ permits tight spatial and temporal regulation of TGFβ signalling [32].
Latent-TGFβ is activated in vitro by a variety of protease and non-protease-dependent mechanisms,
including physiochemical conditions. However, the major activators of TGFβ in vivo are integrins,
most prominently αvβ6 and αvβ8.
3.1. Knockout Mouse Phenotypes
Early indications of integrin involvement in TGFβ activation came from similarities in knockout
mice phenotypes. TGFβ1−/− mice die shortly after birth from multi-organ inflammation and
vasculogenesis defects. TGFβ2−/− mice die around the time of birth with multi-organ developmental
defects. TGFβ3−/− mice develop cleft palate (reviewed in [32]). Integrin β6−/− mice develop lung
and skin inflammation [33]. Moreover, they are protected from bleomycin-induced lung fibrosis,
established as TGFβ1 dependent, and gene expression profiles of the β6−/− lungs show the majority of
TGFβ responsive genes are not upregulated [14,34]. In addition, β6+/+ mice dramatically upregulate
αvβ6 in response to bleomycin, suggesting that αvβ6 expression is important for local activation
of TGFβ1 in epithelial cells [14]. These correlations between increased TGFβ1 activity and αvβ6
expression were confirmed by showing αvβ6-specific antibodies blocked activation of TGFβ1 [14].
The vital role of the RGD integrin-binding sequence in TGFβ1 activation was demonstrated in vivo by
generating mice whose TGFβ1 lacked the integrin recognition motif RGD in LAPβ1 which is replaced
with the inactive motif RGE. TGFβ1RGE/RGE mice exhibit the TGFβ1−/− phenotype despite normal
levels of latent-TGFβ1 [35,36].
Whilst most integrin-β6−/−/β8−/− double knockout mice die in utero, those that survive develop
cleft palate [37], a phenotype replicated in the garp knockout mouse [38], showing that GARP regulates
TGFβ3. Interestingly, replacement of the TGFβ3 gene with TGFβ1 at the TGFβ3 locus partially rescues
palate closures, highlighting that TGFβ3- and TGFβ1-LAP share critical features but also display
isoform-specific roles [39]. Integrin-β8−/− mice have abnormal cerebral and yolk sac vasculogenesis.
Whilst the yolk sac defect is seen in TGFβ1−/− mice, the cerebrovascular defect is not apparent in
TGFβ single isoform knockouts, suggesting overlapping functions in the TGFβ isoforms [40]. A key
observation was that conditional deletion of αvβ8 in dendritic cells (DCs) resulted in widespread
inflammation in the intestines, attributed to failure of DCs to activate TGFβ and thus regulate Treg
activity (discussed below) [41]. Furthermore, pharmacological inhibition of αvβ6 in β8−/− mice
causes a similar phenotype to TGFβ1−/− mice, consistent with αvβ6 and αvβ8 as dominant latent
TGFβ1 activators.
3.2. Ligand Affinity
The RGD integrin-binding motif is present on the LAP propeptides of TGFβ1 and TGFβ3,
which have been shown to bind αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and α8β1 [14,36,42–46].
The homologous latency associated peptide from pro-TGFβ2 has SGD (serine-glycine-aspartic acid) in
place of RGD and binds to αvβ6, but with a thousand-fold lower affinity than LAPβ1 [47] and thus,
is not activated by integrins [48]. LAP-TGFβ1 binds strongly to αvβ6 (10.3 nM) and αvβ8 (13 pM) but
with a significantly lower affinity for αvβ3 (8.5 µM). This nanomolar affinity is unusual in integrins,
which typically bind with lower affinity to allow the reversal of adhesion in retracting regions of
migrating cells. Thus, this high affinity may reflect specialisation to support TGFβ-activation over
cell migration [36,47]. The higher affinity of αvβ6 and αvβ8 for LAP-TGFβ1 is due to the ability to
bind both to RGD and to a second binding motif, LXXL/I which αvβ3, αIIbβ3, and α5β1 are unable to
recognise [47].
3.3. Force-Mediated Activation of ECM Bound Latent TGFβ by αvβ6
When integrins bind to the RGD motif on LAP, association with the actin cytoskeleton triggers
conformational changes in the LLC that releases TGFβ [49,50]. αvβ6 activates latent-TGFβ even in
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the presence of a cocktail of protease inhibitors, indicating a non-protease-dependent mechanism [14].
Furthermore, binding alone of integrins to LAP does not lead to TGFβ activation [1,14,15,22,49,50];
traction forces generated through αvβ6 binding to the LAP of latent TGFβ are required. This activation
is abolished by actin cytoskeleton inhibitors, truncation of the β6-endodomain residues that bind to the
cytoskeleton, or by deletion of the binding site for the latent TGFβ to bind to the ECM that is required
to generate tensile force across the pro-domain [22]. Thus, LAP anchored to the ECM by LTBP and
secured to the cell surface by integrins is distorted by traction between the matrix and cells that permits
liberation of active TGFβ [49–51].
The underpinning mechanism was solved by the Springer group whereby crystal structures of
latent TGFβ revealed a ring-like shape with two LAP prodomain ‘arms’ connected at the ‘elbows’ to
crossed ‘forearms’ formed by two TGFβ monomers and by LAP prodomain ‘straitjacket’ elements
that surrounded each TGFβ monomer (Figure 3). The arms come together at the neck, disulphide
linked in a ‘bowtie’, with RGD motifs located at each ‘shoulder’. The RGD motifs are accessible
for integrins and nearby exposed hydrophobic sidechains on the body of the arm increase affinity
for integrins [15]. αvβ6 binds in a 1:2 complex of the αvβ6 head bound to one monomer of the
latent-TGFβ dimer [9]. The actin cytoskeleton generates the force necessary for TGFβ release from
the αvβ6/pro-TGFβ complex through the β6-subunit cytoplasmic domain, with LTBP anchored to the
ECM providing countertraction [9]. Integrin headpiece opening increases affinity for TGFβ by altering
a β-leg domain orientation and thence, the direction of the force when traction force is applied to the
β-subunit by the actin cytoskeleton [9]. The LAP lasso holds TGFβ within the straitjacket and covers
all of the TGFβ receptors contact sites [15]. RGD motifs are located on opposite sides of the lasso,
so when tensile forces are exerted across them, the lasso is elongated and TGFβ is liberated [9,52].
Figure 3. Force-mediated liberation of TGFβ by αvβ6. Left: TGFβ is held in a ‘straitjacket’ by LAP with
the ‘latency lasso’ preventing covering TGFβ receptor binding sites. αvβ6 activates TGFβ by binding to
RGD motifs on the shoulders of LAP and transducing a force (black arrows) from the actin cytoskeleton.
A resistant counter-force is generated by LTBPs which are bound to LAP by disulphide bonds (SS).
Right: When tensile force is exerted across the structure, the lasso is elongated, the straitjacket unfastens,
and active TGFβ is liberated. Adapted from [15].
This force-dependent mechanism is supported by experiments that demonstrated αvβ5
integrin-dependent release of active TGFβ by contracting myofibroblast cytoskeletons occurs in
a wholly mechanical manner in detergent-treated cells that lack cell membranes or cytosol [53].
Moreover, ferromagnetic beads coated with integrins or anti-LAP beads are capable of liberating TGFβ
from a cell-free matrix [52].
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TGFβ activation by αvβ6 is also dependent on the covalent attachment of LAP to LTBP, specific
ECM-binding regions in LTBP-1, and the presence of fibronectin in the matrix [49,51]. LTBP supports
αvβ6-mediated activation by concentrating and fixing the latent complex. Recombinant SLC that lacks
LTBP fails to activate TGFβ, and LTBP1-derived TGFβ binding cassettes that cannot bind to ECM
prevent αvβ6-mediated activation. However, if the complex is artificially fixed to the pericellular
environment, activation can occur [49]. Fixation of LTBP to the mechano-resistant ECM creates
a resistant ‘holding force’ to the transmembrane ‘pulling force’ of integrins attached to the actin
cytoskeleton, and together, these generate sufficient force to unfasten the straitjacket and liberate TGFβ.
αvβ6 activation is LTBP1-specific, as αvβ6 can activate TGFβ bound to LTBP1, but not LTBP3 [49].
3.4. Activation of GARP-Bound Latent TGFβ on Treg Cells
One of the most powerful pro-tumourigenic functions of TGFβ1 is to promote an immunosuppressive
environment in the TME and recent data highlights the central role of αvβ8 in this process. It has been
known for some time that TGFβ signalling in T cells was required to maintain immune tolerance, since the
genetic abrogation of T-cell TGFβ signalling resulted in lethal autoimmunity [54,55]. The source of the
TGFβ required to promote these signals is only recently becoming clearer. It had also been established
that regulatory T (Treg) cells can produce activated TGFβ1 that can suppress the activity of helper-T
(Th) cells [56,57] and had latent TGFβ1 on their surface membranes [58] in association with GARP [59].
Genetic suppression [59] or antibody [60] inhibition of GARP confirmed that GARP was required
for activation of TGFβ1 by Treg cells but was not sufficient to activate TGFβ1. Thus, the expression
of GARP in HEK293 cells resulted in the surface expression of latent TGFβ1 but no TGFβ1 activity.
Developing upon the mechanisms identified for the activation of ECM bound latent TGFβ all five αv
integrins were assessed for their capacity to activate latent TGFβ on the GARP expressing HEK293
cells; only αvβ6 and αvβ8 generated active TGFβ, but only if the GARP retained its transmembrane
domain; “soluble” GARP-LAP-TGFβ released from cells expressing a transmembrane-deletion mutant
of GARP was not activated by any αv integrins [23]. These data imply (i) that αvβ8 is the principal
activator of GARP-LAP-TGFβ complexes on TReg cells since αvβ6 is epithelial-specific, a prediction
that is now confirmed since either genetic deletion or antibody inhibition of αvβ8 on Treg cells inhibits
activation of cell surface TGFβ [61–63], and (ii) that[the GARP-LAP-TGFβ must be tethered to permit
activation to occur, similar to that of LTBP bound latent-TGFβ. Intriguingly, while αvβ6 forms strong
association with the cytoskeleton through conserved domains [64] within its cytoplasmic tail, αvβ8 has
a divergent cytoplasmic tail that lacks the conserved domains [65] that predict cytoskeletal interaction.
Thus, if αvβ8 mediates the activation of GARP-LAP-TGFβ through force generation, as αvβ6 does for
LTBP1-LAP-TGFβ, the mechanism for generating transmembrane cytoskeletal force remains unclear.
Another similarity between the activation of LTBP1-LAP-TGFβ and GARP-LAP-TGFβ is that
the cell responding to the release/exposure of the mature TGFβ needs to be in contact with the cell
where TGFβ was activated [14,65]. This suggests that either the mature ‘free’ TGFβ1 cytokine is not
released from the Treg surface and remains associated with the GARP-LAP complex, or that, if it is
released, it does not reach the threshold concentration required to suppress Th cells; biologically the
former model is more conservative and provides a much more secure spatio-temporal mechanism for
regulating TGFβ activation in our tissues. The relative importance of one or both mechanisms in vivo
remains unclear.
GARP is expressed by cells other than Tregs, including platelets, megakaryocytes, fibroblasts,
heapatic stellate cells, endothelial cells, some carcinomas, as described in the excellent review by
Stockis et al. [25]. Few formal studies have examined if they also exhibit integrin-dependent local
activation of TGFβ. However, in the context of cancer it is perhaps worth noting the platelets. In a
recent study of mice whereby the GARP protein was selectively deleted from platelets, the amount of
circulating active TGFβ1 reduced significantly and the tumour growth rate was reduced, corresponding
with an increased immune infiltrate into the TME [66]. Thus, platelets require GARP to produce
activated TGFβ and appear to be an important source of both systemic and tumour-associated TGFβ1
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mediating immunosuppression. What is not clear is what, if any, roles integrins play in activating
platelet TGFβ1.
3.5. Metalloprotease-Dependent TGFβ Activation
αvβ8 binds LAP-β1 with high affinity (Kd 13 pM). αvβ8 mediated TGFβ-activation is illustrated
by the inhibition of activation with anti-αvβ8 antibodies [36]. However, the mechanism of activating
ECM-bound TGFβ is distinct from that of αvβ6. As mentioned previously, the β8 cytoplasmic-domain
is dissimilar to any other β-integrins [65] and may be incapable of linking to the actin cytoskeleton [67],
and thus, incapable, directly, of TGFβ-activation by mechanical transduction [36].
The current understanding of αvβ8-mediated TGFβ-activation is that LAPβ1 and LAPβ3 bind
with high affinity to αvβ8 on cell surfaces, and αvβ8 brings the latent complexes into juxtaposition with
a membrane metalloprotease (MMP) which cleaves LAP, releasing TGFβ. This is based on a number of
findings from a single study. Consistent with a proteolytic event, active TGFβ is liberated into tumour
cell line supernatants and into the aqueous phase of lung cancer xenografts by an αvβ8-dependent
mechanism. αvβ8 and MMP-14 co-localise in LAPβ1 substrate contacts and β8-specific RGD inhibitors
and MMP-14 inhibitors both block αvβ8-mediated TGFβ activation, indicating that β8 and MMP-14
are both required. MMP-14 deficient H1264 lung cancer cell lines are unable to activate TGFβ via αvβ8,
whilst the restitution of MMP-14 rescues αvβ8-mediated TGFβ activation. Consistent with LAP-β1 as
the proteolytic substrate of αvβ8-MMP-14-mediated TGFβ activation, β8-overexpressing/MMP-14
expressing H1264 cells cleave and inactivate LAP-β1, whereas β8-overexpressing/MMP-14 deficient
H1264 do not [36].
The mechanism was further supported by the finding that the ability of monocytes to activate
TGFβ also relates to bothαvβ8 and MMP-14. TGFβ activation in monocytes is almost abrogated with an
anti-β8 antibody. Whilst all monocyte subsets express similar amounts αvβ8, only CD14+ monocytes
activate TGFβ, suggesting that as with αvβ6, the mere expression of αvβ8 is insufficient to activate
TGFβ. MMP-14 expression varies ten-fold between CD14+ and CD14− monocytes, and expression
correlates with the ability to activate TGFβ. Antibody inhibition of MMP-14 diminished TGFβ to a
similar degree to anti-β8 antibodies [68].
However, MMP knockout mice do not recapitulate the TGFβ−/− phenotype. Furthermore, whilst it
has been shown that αvβ8 expression on Tregs is vital for TGFβ activation, the authors stated that the
role of MMP-14 was unclear given that Tregs did not have increased expression of MMP-14 compared
with naïve T cells [62]. Moreover, protease inhibitors do not reduce TGFβ activation [63], indicating
that at least in Tregs, αvβ8-mediated TGFβ activation can occur in a non-MMP dependent manner.
3.6. Other Mediators of TGFβ Activation
The higher affinity for LAPβ1 ofαvβ6 andαvβ8 possibly explains their role as the major activators
of TGFβ. However, TGFβ activation can be activated by a number of other integrins.
αvβ5 and αvβ3 are widely expressed and although their respective knockout mice do not
display phenotypes associated with decreased TGFβ activation, they have been shown to activate
TGFβ in vitro when expressed in fibroblasts [45,69]. While the mechanisms were uncertain, there are
hints that MMPs may play a role for some integrins. There is a correlation between activated αvβ3
and MMP-9 expression in breast cancer cells [70] and the localisation of MMP-2 to the surface of
melanoma cells upon interaction with αvβ3 [71]. Both MMP-2 and MMP-9 are capable of activating
TGFβ in vitro [72]. Evidence for mechanical release of TGFβ by αvβ5, αvβ3, and an unidentified β1
integrin was demonstrated in contracting myofibroblast cytoskeletons, with stretching of adherent
myofibroblasts increasing their ability to liberate TGFβ [53]. Based on separate studies, it is likely that
the β1 integrin is αvβ1. Mice with hepatic stellate cells with integrin-αv−/− do not develop carbon
tetrachloride-induced liver fibrosis. However, mice with global knockout of β3, β5 or β6 or conditional
knockout in hepatic stellate cells of β8 do develop liver fibrosis, unless pharmacological blockade of
αv-integrins is administered [73]. αvβ1 has also been implicated as a promotor of bleomycin-induced
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lung fibrosis. Given that this pathology is also established as αvβ6-mediated, this suggests that
multiple integrins can operate simultaneously to regulate TGFβ-mediated stromal responses [14,73].
αvβ3, αvβ5, αvβ6, several β1 integrins and MMP genes are themselves TGFβ transcriptional
targets. Thus, integrin-mediated TGFβ activation can generate self-amplifying feed-forward loops.
In addition, activated TGFβ induces local fibroblasts to differentiate into myofibroblasts which contracts
the ECM. This places anchored LLC under tension and lowers the threshold for activating latent-TGFβ,
augmenting the feed-forward loop and permitting activation by integrins with lower LAP-binding
affinity [45]. Crosstalk amongst integrins also modulates TGFβ activation. Integrin-β1−/− mice or
pharmacological inhibition of β1 induces compensatory upregulation of β3 and increases TGFβ
activation in breast cancer cells. However, the overexpression of β3 did not replicate this phenotype
after β1 loss, implying that there are other modulators of TGFβ in this setting [74].
Physiochemical conditions such as heat and low pH can also unfasten the straitjacket and either
activate TGFβ or lower the activation threshold [32]. Of note is the diverse range of non-integrin proteins
that have been associated with TGFβ activation and are discussed comprehensively elsewhere [22].
4. TGFβ Signalling
Having liberated/exposed the mature TGFβ cytokine, it can interact with its cognate receptors and
promote a variety of intracellular pathways. TGFβ signaling is described by many excellent reviews
including [3,4,17,21] and the following is just a brief overview.
Once activated, TGFβ triggers signalling in cells by binding to the TGFβ serine/threonine kinase
receptor complex. Upon binding to TGFβ receptor 2 (TGFβR2), TGFβ receptor 1 (TGFβR1) is recruited,
transphosphorylated and activated. Serine/threonine protein kinases in the intracellular domain
leads to the recruitment and phosphorylation of the intracellular downstream mediators Smad2 and
Smad3. Oligomerisation of phosphorylated Smad2 and Smad3 with Smad4 permits translocation to the
nucleus where they act as a transcriptional complex. Inhibitory Smads, including Smad6 and Smad7,
regulate the pathway [16,17,21,32,75–79]. The oligomers of Smads acquire different stoichiometries,
permitting different signalling thresholds of gene expression [21,80]. TGFβR3 (β-glycan) can amplify
the signalling cascade by binding TGF-β and promoting presentation to TGFβR2 [16,17,78]. TGFβ2
has a lower binding affinity than TGFβ1 and TGFβ3 and therefore, relies on β-glycan for high-affinity
binding to the TGFβ receptor complex. Therefore, in endothelial and haematopoietic cells that do not
express β-glycan, TGFβ2 has a limited activity [81,82].
Smad target genes interact with a range of transcription factors. Interactions between these
co-activators and co-repressors define the degree of transcription. Although Smads bind to DNA with
a 100-fold lower affinity than high-affinity transcription factors, they are required for transcriptional
activation [21]. TGFβ receptors remain active for several hours after ligand binding, and repeated
receptor activation maintains Smad complexes within the nucleus [83].
The canonical TGFβ pathway is Smad-mediated. Smad-independent TGFβ-activated signalling
pathways mediate a non-canonical pathway that includes the PI3K-AKT, Ras/ERK, p38 kinase, and small
GTPase (RHOA, PKN, Rock) pathways [16,21,75,84]. Both Smad- and non-Smad dependent pathways
may induce TGFβ1 expression, thus amplifying the TGFβ response [85]. Although the converging
pathways usually results in cooperativity, pathways may counteract each other [21].
5. TGFβ in Cancer
TGFβ has a dichotomous role in cancer, emerging as a positive prognostic factor in early tumours,
yet as a poor prognostic marker in advanced tumours [77]. A definitive “switch” from tumour
suppressor to promoter is not evident. Rather, an accumulation of genetic, epigenetic and cellular
events in canonical and non-canonical pathways within cancer cells and the TME drive a phenotype of
decreased TGFβ responsiveness and the increased expression or activation of TGFβ ligands [17,86,87].
The role of TGFβ in cancers can broadly be categorised into effects on cell proliferation, induction
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of epithelial to mesenchymal transition (EMT), modulation of the TME, and dampening of immune
surveillance [88–90]. Below we outline these actions, focusing on the role of integrins.
5.1. Proliferation
In normal tissues, TGFβ counteracts proliferation primarily by inhibiting cell-cycle progression
with G1 arrest and stimulation of cyclin-dependent kinase inhibitors [2,20]. This is demonstrated
in vivo where integrin β8-expressing cancer cells are less tumorigenic and have slower growth
mediated by increased TGFβ activation [36]. However in cancer, growth-inhibitory effects of TGFβ are
eventually overcome by either “decapitation” of core pathway components—TGFβ receptors or Smad
transcription factors, or the loss of downstream signalling targets [77]. Within the TGFβ pathway,
loss of function mutations are most common, particularly in gastrointestinal cancers [91], notably
in pancreatic cancers and colorectal cancers (up to 100% and 83% of patients respectively) [92,93].
Truncated, functionally inactive TGFβR2 is associated with high microsatellite instability cancers [2,77]
and Smad4 is mutated in about half of pancreatic, colon, and oesophageal cancers [77].
A number of experimental findings support the increased tumorigenicity associated with abrogated
or dysfunctional TGFβ pathways. In normal keratinocytes, TGFβ1 knockout or expression of
dominant-negative TGFβR2 causes genomic instability and malignant transformation [94]. Cancer cells
that have lost sensitivity to TGFβ due to mutations in TGFβR1 but can be re-sensitised by re-expression
of TGFβR1, also resulting in reduced tumour formation [95].
Integrins are also implicated. A large fraction of integrin-β6−/− mice have spontaneously occurring
tumours, with the phenotype linked to deficient TGFβ activity [96]. αvβ6 blockade increases tumour
cell proliferation in both early and late stage disease, depending on the presence of Smad4 [97].
In addition, inappropriate α6β4 expression in stratified squamous epithelia has been found to inhibit
TGF-β signalling and increase tumorgenicity by impeding TGFβ-mediated suppression of clonal
expansion of initiated cells within the epidermal basal layer [98,99].
5.2. EMT & Metastasis
Epithelial-mesenchymal transition (EMT) is a process by which epithelial cells lose or reduce
cell–cell and cell–substrate adhesion and transition to a more mesenchymal-like phenotype, aiding
migration, invasion, and metastatic spread [100]. The loss of E-cadherin, typically located at cell–cell
adhesion junctions and essential for maintaining an epithelial phenotype, is a hallmark of EMT [101].
The TGFβ pathway can mediate the entire switch from epithelial to mesenchymal phenotype by
repression of epithelial gene signatures, including E-cadherin, and the elevation of mesenchymal genes
such as α-SMA and vimentin [42,102]. Smad-mediated pathways induce the loss of cellular adhesion
and non-canonical pathways, particularly as RHO and AKT promote migration and invasion [103–105].
Integrins potentiate TGFβ-mediated E-cadherin downregulation. In renal cancer cells, cyclo-RGD
peptide αvβ3 ligand and TGFβ1 inhibit E-cadherin with a synergistic effect [106]. During EMT of
mammary epithelial cells, β1-integrins induce TGFβ dependent p38 MAPK activity [107]. In basal
cell carcinoma organotypics, αvβ6-mediated TGFβ activation induces differentiation of fibroblast
into myofibroblasts with subsequent induction of tumour cell invasion [108]. Similar effects have
been shown with α5β1, αvβ3, and αvβ5. These other integrins are not normally highly expressed in
epithelial cells but are induced by TGFβ signalling, consistent with the feed-forward loop discussed
earlier. Antagonising TGFβ in these cells blocks induction of these integrins and reduces invasion
and metastasis [109], indicating that the inhibition of integrin-mediated TGFβ pathways may reduce
metastasis. Indeed, TGFβ responsive stromal signalling has been demonstrated to drive metastasis.
In breast cancer cells, it has been shown to promote single cell motility and intravasation and to be
essential for blood-borne metastases [110]. In Her2-positive breast cancer xenografts, αvβ6-expression
is associated with increased metastases, and treatment with the anti-αvβ6/αvβ8 antibody causes
decreased metastases and pSmad2 [111]. In breast ductal carcinoma in situ, αvβ6 expression is
associated with progression to invasive cancer. In studies to elucidate the mechanism, overexpression
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of β6 in myoepithelial cells was found to activate TGFβ1 and upregulate MMP9. The blockade of
either MMP or TGFβ inhibited the ability of β6+ myoepithelial cells to promote invasion, suggesting
that αvβ6 mediates TGFβ promotion of an invasive phenotype [112].
In colon cancer organoids and in vivo models, transcriptional activation of integrin-αvβ6 enhances
tumorgenicity, with autocrine TGFβ implicated as the mediator. In patients with colon cancer, tumour
αvβ6-expression is a powerful prognostic marker with a median survival of 16.5 vs 4.8 years in those with
low vs high expression [113]. Similarly, in squamous cell carcinoma organotypics, collagen-7 deletion
induced increased invasion, αvβ6 upregulation, and increased matrix fibronectin. These findings were
suppressed by co-inhibition with TGFβR1 inhibitors. In vivo similar results were observed, along
with increased pSmad2/3 signalling in the stroma of collagen-7 deficient SCC tumours, implying that
collagen-7 acts as a TGFβ suppressor, and consistent with αvβ6-dependent TGFβ1 activation inducing
fibroblast to myofibroblast transition [114].
TGFβ signalling is central to the formation of bone metastases and osteolytic destruction of
adjacent bone in both prostate and breast cancers, with TGFβ blockade inhibiting bone metasteses
development [115–117]. αvβ6 has been shown to be expressed in prostate cancer bone metastases,
and in vivo models of bone metastasis have shown thatαvβ6 promotes osteolysis through upregulation
of MMP-2 and parathyroid hormone-related protein [118]. A subsequent study revealed that αvβ6
was required for TGFβ1-mediated MMP-2 expression in prostate cancer cells [119]. Of note is the
fact that in this study, αvβ6 induced TGFβ signalling by interacting with TGFβR2; although a direct
association between and αvβ6-TGFβR2 was not fully confirmed [119].
5.3. Angiogenesis
Blood vessel proliferation permits tumour growth by providing adequate nutrient supplies,
removal of waste products, and routes for metastasis [120]. Pancreatic cancer cells with activated TGFβ
induce angiogenesis when implanted into mice [121] whilst TGFβ-blocking antibodies or targeted
deletion of TGFβ in mice results in decreased angiogenesis [122]. Epithelial cells with activated TGFβ
show increased gene expression of the pro-angiogenic vascular endothelial growth factor (VEGF)
and thrombospondin [17]. Of note, the TGFβ effects appear concentration-dependent. In endothelial
cells, sheets derived from mouse metatarsals low TGFβ concentrations are pro-angiogenic, but high
concentrations are anti-angiogenic. Furthermore, in this setting, integrin-α5β1 is a key mediator
of TGFβR1 and VEGF promotion of angiogenesis. TGFβR1 inhibitors and VEGF synergistically
upregulate α5 and β3 integrin gene expression, with downregulation or antibody blockade of α5
inhibiting this co-operative effect [123,124]. Similarly, αvβ3 and αvβ5 deletion accelerates tumour
angiogenesis through increased expression of VEGF2 and sensitivity to VEGF-A [125,126].
αvβ8 is also implicated in tumour angiogenesis. Integrin-β8−/− mice develop abnormal cerebral
vasculogenesis [37,127]. In glioma, orthotopically implanted β8-high astrocytoma cells develop
microscopic non-haemorrhagic tumours with uniform vessels, whereas β8-low cells cause large
haemorrhagic tumours with an abundant vasculature and a lower Smad2/3 expression in endothelial
cells, implying TGFβ-mediation [128].
5.4. Stroma
TGFβ modulates the ECM by different mechanisms. TGFβ promotes fibroblast-to-myofibroblast
transdifferentiation and stimulates cancer-associated fibroblasts (CAF) to produce ECM- and
cell-adhesion proteins including integrins, collagen, and fibronectin [17,129]. Integrins are also
implicated as mediating this process in CAFs—another feed-forward loop [10,130]. TGFβ-induced
mesangial cell collagen expression has been shown to require integrin-mediated FAK activation [131]
and α3β1 potentiates TGFβ-induction of MMP-9 in immortalised keratinocytes [132].
Stromal TGFβR2 expression decreases with tumour progression and is a poor prognostic marker
in colorectal cancer [17,133]. The attenuation of TGFβ at either receptor or Smad level results in
increased myeloid-derived suppressor cells and stromal fibroblast activation, driven by increases in
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CXCL1 and CXCL5 expression, which are normally inhibited by TGFβ. This is demonstrated in vivo by
increased desmoplasia and angiogenesis in mice pancreatic epithelium expressing a dominant-negative
TGFβ-receptor [17].
A number of studies have implicated αvβ6 as a mediator of TGFβ-induced stromal changes.
αvβ6 blockade with the antibody 6.3G9 in Detroit-562 pharyngeal tumour cells had no effect on
TGFβ-mediated proliferation in vitro, but did inhibit in vivo xenograft tumour growth, suggesting
that the TME has an important regulatory role. αvβ6 expression in the stroma correlated with
α-SMA, although treatment had no effect on stromal collagen and smooth muscle actin levels [134].
A similar study in Detroit-562 also found limited effects in vitro when treated with 264RAD and a
dose-dependent reduction of tumour growth in vivo, which, in this study, was associated with reduced
stromal fibronectin and α-SMA [134–136]. This difference may be due to the additional blockade
of αvβ8 with 264RAD, which was not explored at the time. 264RAD also reduces stromal α-SMA
expression in MCF7 and HER2-18 breast cancer xenografts with associated Smad2 reductions [111].
Similarly, a subset of non-small cell lung cancer (NSCLC) cell lines co-cultured with fibroblasts
induced an activated CAF phenotype with α-SMA expression. CAF activation was associated
with αvβ6, and activation was blocked by either 264RAD or the TGFβR kinase inhibitor SB321542.
However, after three days co-culture, only SB321542 was effective, indicating that whilst initial CAF
activation was αvβ6-dependent, once activated, alternative TGFβ activating pathways maintain the
phenotype [53,136]. Treatment of αvβ6-expressing transgenic pancreatic ductal adenocarcinoma
(PDAC) with 264RAD plus gemcitabine significantly increased overall survival compared with
gemcitabine alone and was associated with reductions in both pSmad3 and nuclear Smad4 levels,
as well as reductions in αSMA-positive fibroblasts and blood vessel density, both targets of TGFβ
signalling [137].
Whilst the consensus is that TGFβ1 activated CAF rich stroma is tumour-promoting, conflicting
data exist. For example, in transgenic PDAC mice models, depletion of α-SMA-expressing cells,
designed to eliminate CAFs, unexpectedly induced invasive undifferentiated tumours with poorer
survival, despite associated reductions in fibrosis in both advanced and precursor lesions. Fewer tumour
myofibroblasts were also associated with poorer survival in patients with pancreatic cancer. In the
mice, the reduced fibrosis was strongly associated with increased Tregs [138]. Separate studies have
also found that sonic hedgehog pathway inhibition in mouse pancreatic cancer models reduces
stromal density but causes more aggressive tumours [139]. A subsequent study showed that PDAC
stroma has at least two types of CAFs, inflammatory (iCAF) and αSMA-expressing myofibroblasts
(myCAFs) that had distinct transcriptional and secretory profiles and were likely to affect tumour
growth differently [140]. Thus, the earlier study [138] would have eliminated only the myCAFs and
left the iCAFs present. In a recent study, at least four types of pancreatic stellate cell (a specialized
pancreatic fibroblast) existed, suggesting even greater heterogeneity [141]. It has not been established
whether each subtype responds differently to TGFβ, nor which are tumour-promoting or suppressive.
Thus, caution would be prudent when therapeutically targeting CAFs in PDAC, and one assumes
cancers in other tissues as well, as it is not clear which types of CAF are the tumour-promoting cells.
Recently, studies have identified exosomes as mediators of TGFβ activation between cancer cells
and the TME through horizontal propagation of integrin-assoicated phenotypes in a paracrine manner.
Integrin-expressing exosomes can directly transfer integrins to target cells [142,143], with transfer from
cancer cells to benign cells inducing an αv integrin-mediated aggressive migratory phenotype [144].
Exosomally transported αvβ6 from gut epithelial cells have been shown to be transferred to mucosal
dendritic cells, expressed on the surface, activate local TGFβ, and confer tolerogenic properties to
dendritic cells including induction of TGFβ production by Tregs [145]. Within cancer, prostate cancer
cells have been shown to efficiently transfer αvβ6 via exosomes to αvβ6 negative cells and localize to
the cell surface with subsequent enhanced adhesion and LAP-TGFβ migration in vitro [146], although
it remains to be seen whether this occurs in stromal cells within the TME. Cancer exosomes are also
implicated in increased TGFβ signaling. Exosomes purified from stromal fibroblasts from patients
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with oral squamous cell cancer (SCC) have been demonstrated to contain TGFβR2, and when these
exosomes are transferred into TGFβR2-deficient SCC keratinocytes, TGFβ signaling increases [147].
5.5. Immunomodulation
Tumour progression is aided by promoting regulatory immune cell subsets and dampening
anti-tumour immunity. TGFβ influences these processes in both the innate and adaptive immune
systems. High tumour TGFβ concentrations attracts myeloid and lymphoid cells as described
previously [17,87,133,148]. Accordingly, it may be that the immunosuppressive function of TGFβ
can be modulated or even abrogated by modulating the extent of TGFβ activation rather than TGFβ
production [149], inferring a possible role for integrins.
Many of the effects of TGFβ on immune cells result from an ability to polarise cells towards
an alternative differentiation status that is immunosuppressive and pro-tumorgenic (excellently
reviewed in [150]). TGFβ induces pro-tumourigenic ‘M2’-macrophages and their presence is a
poor prognostic marker in many cancers including ovarian, breast, gall-bladder, oral, oesophageal,
and non-small cell lung carcinoma [151,152]. αvβ6 is independently associated with the induction of
M2 macrophages, with demonstration in prostate cancer that αvβ6 containing exosomes are transferred
to monocytes and promote M2 polorisation, whereas αvβ6 downregulation in exosomes inhibited M2
polarisation [153]. The study implicates αvβ6-mediated modulation of the STAT1/MX1/2 signaling
pathway, but whether αvβ6-mediated TGFβ activation contributes is unclear. Neutrophils can also
acquire a tumour permissive ‘N2’ phenotype in a TGFβ-dependent manner, with a subset of low-density
neutrophils shown to accumulate with tumour progression [154,155]. TGFβ also inhibits NK cell
maturation [156,157].
The loss of Smad4 signalling in T cells, but not in epithelial cells, is associated with spontaneous
epithelial cancer formation throughout the gastrointestinal tract in mice [158]. TGFβ has been shown
to directly suppress CD8+ cytotoxic T-lymphocyte (CTL) function through transcriptional repression of
key proteins including perforin, granzyme, and cytototoxins [159]. Tregs act to counter CTL activity and
maintain immunological tolerance. Treg accumulation is associated with poor survival, particularly in
cervical, renal, melanoma, breast, liver, and gastric cancer [160]. Thus, TGFβ promotion of Treg activity
is a significant contributor to tumour progression. Similar multi-organ inflammation of TGFβ−/−
mice is seen with TGFβ signalling abrogation specifically in T-cells, implying T-cell mediation of
the TGFβ−/− phenotype [54,161]. Treatment of naïve T-cells with TGFβ can induce differentiation to
Tregs [87,159,162], which, in liver cancer has been shown to be mediated by CCL22 promotion [163].
αvβ8-mediated TGFβ activation is crucial in preventing anti-tumour immunity through
enhanced Treg activity. Integrin-αvβ8 is expressed in Tregs, but not naïve T-cells. Studies have
indicated that Tregs require αvβ8 to liberate TGFβ1 from the GARP complex, that αvβ8-deficient
Tregs are incapable of inducing differentiation of naïve T cells, and that β8 expressed by Tregs
can suppress aberrant T-cell-mediated inflammation [61,62]. Accordingly, mice with conditional
knockout of αvβ8 on antigen-presenting DCs develop increased T-cell activation with consequential
autoimmunity [41,68,164]. It is possible that tolerance is induced by αvβ8 on DCs releasing TGFβ
from Tregs via cell-cell contact, inducing a larger Treg pool [23]. As described above, Tregs have been
shown to be specialised activators of TGFβ via αvβ8 expression. Tregs express 50–100-fold higher
levels of integrin-β8 and increased ability to activate latent-TGFβ than naïve and effector memory T
cells. Unlike Tregs, β8-knockout Tregs are unable to supress CD4+ T cell expansion in vivo, indicating
αvβ8 is necessary to limit this effector T-cell function [62]. In addition, anti-β8 antibodies have been
shown to block Treg-mediated immunosuppression in vivo [63].
Macrophages also activate TGFβ through an αvβ8-dependent mechanism that can counter
pro-inflammatory cytokine production. This is supported by the finding that αvβ8 is upregulated on
M2-macrophages and downregulated on pro-inflammatory M1-macrophages, and also by the ability
to almost fully suppress TGFβ activation in monocytes treated with anti-αvβ8 antibodies [68].
Cancers 2019, 11, 1221 13 of 24
Crucially, TGFβ inhibition has been shown to modulate antitumour immune responses with
enough potency to mediate tumour regression. Preclinically, transgenic mice with EL-4 thymoma
or B16-F10 melanoma xenografts grown in mice with T cells deficient in TGFβ signalling generate
tumour-specific CTLs that eradicate tumours [165]. In colorectal cancer mouse models, TGFβ is a
primary mechanism of immune evasion that promotes T-cell exclusion and inhibits CTL maturation,
and although PD-1 or PD-L1 immune checkpoint inhibition has limited efficacy, TGFβR1 inhibition
with galunisertib produces potent and enduring anti-tumour T-cell responses, and rendered tumours
susceptible to anti-PD-L1 therapy. Galunisertib efficacy was abolished with the depletion of CD8
T-cells, indicating efficacy was through augmentation of anti-tumour immunity rather than other TGFβ
mechanisms [166]. Similarly, in a melanoma model, B16 tumours-derived Tregs were able to suppress
CTL-mediated killing of explanted tumour cells, with restoration by neutralising antibodies against
TGFβ on the Tregs [167].
Excitingly, TGFβ has recently been identified as a key source of resistance to immune checkpoint
inhibitors in patients. In a large trial of patients with metastatic urothelial cancer treated with the
anti-PD-L1 antibody atezolizumab, a lack of response was associated with a TGFβ signature on
fibroblasts in the TME. Tumours were found to exhibit three distinct immune phenotypes—inflamed,
excluded, or desert [168,169]. The TGFβ signature was only associated with lack of response in the
excluded tumours, consistent with TGFβ-mediated fibroblast activation in the TME. In associated
studies in mice with EMT6 breast cancer tumours, which display an immune-excluded phenotype,
treatment with either TGFβ or PD-L1 blocking therapy had a minimal effect, but combination
treatment led to increased tumour infiltrating T-cells and tumour regression. Combination therapy
had limited impact on T-cell or macrophage TGFβ signatures, and thus, the efficacy was attributed to
reprogramming stromal fibroblasts and increased TME CTLs [170].
6. Therapeutic Targeting of TGFβ
TGFβ inhibitors have as yet failed to deliver the anticipated clinical efficacy [86,171,172]. Recent
findings have highlighted that the principal anti-tumour effect of global TGFβ inhibitors may not be
against cancer cells as originally believed, but by modulating the TME, as discussed above. Thus,
combination therapy with agents that target cell proliferation may elucidate a clearer role for TGFβ
inhibitors. Given the role of αv-integrins in liberating active TGFβ, therapeutic inhibition of surface
αv-integrin expression may be a more effective method of suppressing local TGFβ activation than current
therapies which predominantly inhibit TGFβ receptor activation or downstream signal transduction.
Furthermore, the inhibition of αv-integrins may interrupt the feedforward loop of TGFβ activation
described several times in this review and thus, prevent self-amplifying tumour-stroma interactions
that lead to malignant progression. The most significant potential role will be in patients with tumours
where αvβ6 is a poor prognostic marker, notably colon [113], cervix [173], lung [124], and breast
cancers [111], and in cancers with high αvβ6 expression, notably pancreatic [174], oesophageal [134],
and skin cancer [134]. Certainly, some pre-clinical data suggest that blockade of αvβ6 does suppress
local TGFβ signaling [114,132,135].
Of the integrins that activate TGFβ, only anti-αvβ3 antibodies and peptides have been evaluated
in patients, none with clinical success [175,176]. The pan-αv blocking antibody abituzumab was
evaluated with or without standard therapy in metastatic colorectal cancer. Whilst overall, there was
no survival benefit, in patients with high αvβ6 tumour expression, the risk of death was reduced by
59% with abituzumab [177]. However, no endpoints relating to TGFβ are available. Cilengitide was
evaluated in glioblastoma in two large clinical trials: CENTRIC (Phase 3) [178], and CORE (Phase
2) [179]. Tumour avβ3 expression was associated with improved survival in patients treated with
cilengitide in CORE, but not CENTRIC. However, in CORE there was no evidence that pSMAD
levels changed in relation to αvβ3/αvβ5 levels, indicating that survival may not be controlled by
αvβ3/αvβ5-dependent TGFβ process [180]. It is worth noting that the discovery that GARP is required
for Treg activation of TGFβ and thus functionality and that antibodies to GARP can inhibit this
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process has resulted in investigations of GARP as a therapeutic target for suppressing Treg-dependent
pathologies (discussed in [25]).
Anti-PD-1, PD-L1, and CTLA-4 immune checkpoint inhibitors are licensed in a number of cancers,
with remarkably potent and durable anti-tumour effects in a subset of patients [181]. Given that around
70–80% of patients experience side effects, yet less than a third of patients benefit from the expensive
therapy, elucidating biomarkers for response or resistance is vital [182–185]. Thus, the ability to use
a TGFβ signature to identify patients with urothelial cancer that are unlikely to benefit from PD-L1
inhibition is clinically very useful, and it will be interesting to see if it translates to other cancers.
The finding that combination TGFβ and PD-L1 overcomes resistance to PD-L1 checkpoint-blockade is
exciting and will undoubtedly be evaluated clinically to see if the benefits of checkpoint inhibitors can
be extended to more patients [170]. However, over 70% of patients treated with checkpoint inhibitors
develop autoimmune related toxicity [186], and given the TGFβ−/− inflammatory phenotype discussed
earlier, a potential concern is that combination therapy may be too toxic. Again, local targeting of
TGFβ by integrin inhibition may overcome this issue, although as yet, very little has been published
on the effect on the immune microenvironment when integrins are targeted in cancer. In advanced
carcinomas, targeting of both αvβ6 and αvβ8 to eliminate the TGFβ producing capacity of the tumour,
monocytes, dendritic cells and Tregs, would seem an appropriate future strategy.
7. Conclusions
TGFβ has a dichotomous role in cancer. In normal tissue and early tumours, it acts as a potent
tumour suppressor, but with loss or inactivation of TGFβ downstream signalling it becomes a tumour
promotor, inducing EMT, metastasis, angiogenesis, stromal changes and an immunosuppressive TME.
TGFβ has been implicated as a key mediator of resistance to immune checkpoint inhibitors in patients,
and combination therapy in mice with TGFβ inhibitors has been shown to overcome this resistance.
However, global inhibitors of TGFβ have failed to achieve the clinical benefits expected owing to
co-suppression of TGFβ-dependent homeostatic activities that resulted in off-target toxicity. Thus local
tissue inhibition of TGFβ activation may offer improved therapeutic outcomes.
Integrins αvβ6 and αvβ8 are specialised to liberate TGFβ from the latent complex in which it is
embedded in the ECM or on the surface of immunosuppressive Tregs and monocytes. Experimentally
studies inhibiting of αvβ6 or αvβ8 have resulted in reduced TGFβ signaling, reduced cancer
growth, reduced tumour immunosuppression and changes in the TME that suggest a less permissive
environment. These data offer hope that similar observations might be possible in humans. Additionally,
antibody inhibition of GARP may offer a more selective means to reduce tumour immunosuppression
mediated by Tregs and monocytes. Integrins other than αvβ6 and αvβ8 may activate TGFβ when the
threshold for activation is lowered, such as when the ECM is under tension, as it would be during
a fibrotic stage of growth. This can result in cross-talk between integrins and TGFβ production and
activation that can mediate a self-amplifying feed-forward loop of TGFβ activation.
As yet, it remains unclear how anti-integrin therapies affect the tumour immune microenvironment.
However, it is worth investigating if such therapies may be superior to specific TGFβ or TGFβ pathway
inhibitors in reducing TME immunosuppression and augmenting the anti-tumour immunity mediated
by checkpoint inhibitors and other biotherapeutics such as chimeric antigen receptor-T cells.
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